Off-Label Dosing of Non-Vitamin K Antagonist Oral Anticoagulants and Adverse Outcomes-Reference-Cited by-同舟云学术

Off-Label Dosing of Non-Vitamin K Antagonist Oral Anticoagulants and Adverse Outcomes

Published:2016-12 Issue:24 Volume:68 Page:2597-2604
ISSN:0735-1097
Container-title:Journal of the American College of Cardiology
language:en
Short-container-title:Journal of the American College of Cardiology

Author:

Steinberg Benjamin A.,Shrader Peter,Thomas Laine,Ansell Jack,Fonarow Gregg C.,Gersh Bernard J.,Kowey Peter R.,Mahaffey Kenneth W.,Naccarelli Gerald,Reiffel James,Singer Daniel E.,Peterson Eric D.,Piccini Jonathan P.

Publisher

Elsevier BV

Subject

Cardiology and Cardiovascular Medicine

Reference20 articles.

1. Comparison of the efficacy and safety of new oral anticoagulants with warfarin in patients with atrial fibrillation: a meta-analysis of randomised trials;Ruff;Lancet,2014

2. Dabigatran versus warfarin in patients with atrial fibrillation;Connolly;N Engl J Med,2009

3. Apixaban versus warfarin in patients with atrial fibrillation;Granger;N Engl J Med,2011

4. Rivaroxaban versus warfarin in nonvalvular atrial fibrillation;Patel;N Engl J Med,2011

5. Edoxaban versus warfarin in patients with atrial fibrillation;Giugliano;N Engl J Med,2013

Cited by 428 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. Appropriateness of direct oral anticoagulant dosing in patients with atrial fibrillation at a tertiary care hospital in Thailand;Exploratory Research in Clinical and Social Pharmacy;2024-12

2. The use of reduced DOAC doses in atrial fibrillation patients does not always lead to good anticoagulation levels and avoid adverse events;International Journal of Cardiology;2024-12

3. Pharmacist Use of a Population Management Dashboard for Safe Anticoagulant Prescribing: Evaluation of a Nationwide Implementation Effort;Journal of the American Heart Association;2024-09-09

4. Residual Stroke Risk Among Patients With Atrial Fibrillation Prescribed Oral Anticoagulants: A Patient‐Level Meta‐Analysis From COMBINE AF;Journal of the American Heart Association;2024-09-03

5. Dose Reduction of Edoxaban in Patients 80 Years and Older With Atrial Fibrillation;JAMA Cardiology;2024-09-01